Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Core Insights - Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201 for relapsed/refractory AL Amyloidosis, a rare blood disease with no current FDA-approved therapies [1][2] Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis [6] - The company is focused on developing NXC-201, a CAR-T cell therapy designed to target and eliminate toxic light chains produced in AL Amyloidosis [5][7] Product Details - NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy that has received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) from the FDA [5][7] - The therapy aims to address a significant unmet medical need in relapsed/refractory AL Amyloidosis, which is characterized by organ failure and high mortality rates [2][3] Market Insights - The AL Amyloidosis patient population in the U.S. is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [3] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025 [4]